Ophthalmic adverse events under tofacitinib and baricitinib: Case analysis of the European Pharmacovigilance Database

Joint Bone Spine. 2023 Jan;90(1):105483. doi: 10.1016/j.jbspin.2022.105483. Epub 2022 Nov 9.

¹ Department of Rheumatology, Besançon University Medical Center, Besançon, France; EA 4267 "PEPITE", FHU Increase, Bourgogne-Franche Comte University, UFR SMP, Besançon, France.
² Department of Pharmacovigilance, Besançon University Medical Center, Besançon, France.
³ Department of Pharmacovigilance, Grenoble University Medical Center, Besançon, France.
⁴ Department of Ophthalmology, Besançon University Medical Center, Besançon, France.
⁵ Department of Rheumatology, Cochin University Hospital, Paris, France.
⁶ Department of Rheumatology, Besançon University Medical Center, Besançon, France; EA 4266 "EPILAB", Bourgogne-Franche Comte University, UFR SMP, Besançon, France. Electronic address: dwendling@chu-besancon.fr.

No abstract available

Keywords: Jak inhibitors; Keratitis; Ocular manifestations; Pharmacovigilance; Rheumatoid arthritis; Scleritis; Spondyloarthritis; Uveitis.

Publication types